• TH287 MTH1 Inhibitor: Reliable Cell Assays

  2026-08-21

  Learn how TH287 MTH1 inhibitor, SKU B5849, can support reproducible viability, apoptosis, and radiosensitization experiments. This scenario-based guide connects formulation details with published evidence on oxidized nucleotide stress, DNA damage, and treatment timing.

• 10 mM dNTP mixture for PCR and DNA synthesis

  2026-08-20

  Build more consistent PCR, qPCR, sequencing, and DNA synthesis workflows with an equimolar nucleotide source designed for controlled DNA polymerization. This guide also shows how standardized DNA preparation can support, but should not be confused with, lipid nanoparticle trafficking studies.

• Tc3-Induced Pyroptosis in Hepatic Carcinoma

  2026-08-20

  A 2025 Theranostics study identified the indole analogue Tc3 as a gasdermin E-mediated pyroptosis inducer that suppresses hepatic carcinoma growth. The work also provides preclinical evidence that Tc3 can improve cisplatin activity and cooperate with anti-PD-1 treatment, while highlighting GSDME expression and tumor immune activation as important response factors.

• Triacetin in Ocular and Metabolic Research

  2026-08-19

  Triacetin, also called glyceryl triacetate, is more than an inert formulation aid: it can influence cellular, metabolic, and assay outcomes. This evidence-focused guide explains how ocular nanoemulsion research can improve Triacetin controls, interpretation, and translational decision-making.

• Annexin V-APC/7-AAD Apoptosis Kit: Assay Logic

  2026-08-19

  The Annexin V-APC/7-AAD Apoptosis Kit converts phosphatidylserine exposure and membrane integrity into an interpretable cell-death map. This guide connects assay design, flow-cytometry controls, and the PSA-CD56/Siglec-7 findings in clear cell renal cell carcinoma.

• MK-571: Decoding Macrophage Protection Assays

  2026-08-18

  MK-571 (L-660,711) is more than a leukotriene receptor antagonist: it is a powerful probe for separating cysLT1 signaling from ABCC1/MRP1-mediated drug transport. This article explains how recent macrophage findings should reshape assay design, controls, and interpretation.

• Brinzolamide Nanoemulsions: Ocular Safety and Permeation

  2026-08-18

  The reference study developed and screened brinzolamide-loaded nanoemulsions using complementary corneal permeation, retinal-cell viability, HET-CAM, and BCOP assays. Its main contribution was to connect improved ex vivo delivery with preliminary ocular safety, identifying formulation candidates that outperformed a marketed suspension without overstating their clinical readiness.

• GW 4869: Exosome Workflows in Lupus Nephritis

  2026-08-17

  GW 4869 hydrochloride hydrate enables a practical donor–recipient strategy for testing whether extracellular vesicle release contributes to glomerular endothelial injury. This guide combines neutral sphingomyelinase inhibition with cargo validation, normalization, and toxicity controls so reduced signaling is not mistaken for nonspecific cell damage.

• Pexidartinib (PLX3397) and CSF1R Translation

  2026-08-17

  Pexidartinib (PLX3397) offers a mechanistically focused way to interrogate CSF1R biology, macrophage behavior, and tumor–immune interactions. This thought-leadership article connects its use in cancer research with neuroimmune findings on microglial activation, while emphasizing experimental controls, translational boundaries, and opportunities beyond conventional product-page descriptions.

• Beyond Monocultures: Crizotinib in Tumor Assembloids

  2026-08-16

  Patient-derived gastric cancer assembloids expose how stromal context reshapes drug response. This article examines how Crizotinib hydrochloride can serve as a mechanistic probe for ALK, c-Met, and ROS1 signaling in translational cancer research.

• In Vitro Drug Response: Viability Versus Cell Death

  2026-08-15

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but non-equivalent dimensions of anticancer drug response. Its central practical implication is that cancer research workflows should separate proliferative arrest from death and consider their relative timing rather than treating one viability value as a complete pharmacologic profile.

• Demethyleneberberine: Applied Research Workflows

  2026-08-14

  Demethyleneberberine (DMB) is a versatile research compound for connecting inflammatory, mitochondrial, neurodegenerative, and cancer phenotypes to measurable signaling events. This workflow-focused guide covers formulation, model selection, pathway assays, dose translation, and troubleshooting for more reproducible results.

• Direct Mouse Genotyping Kit Plus for Atherosclerosis

  2026-08-14

  The Direct Mouse Genotyping Kit Plus turns small mouse tissue samples into PCR-ready lysates, helping researchers verify alleles, screen colonies, and organize cardiovascular studies with fewer purification steps. Its 2X high-fidelity PCR master mix with dye reagents also simplifies gel-based interpretation when genotyping EP4- or ApoE-related mouse models.

• Mubritinib (TAK 165): An OXPHOS Assay Guide

  2026-08-13

  Mubritinib, also known as TAK 165, is more informative as a mitochondrial complex I probe than as a conventional HER2 inhibitor. This guide translates AML and PEL evidence into practical assay-design decisions, including metabolic readouts, controls, dosing, and interpretation limits.

• Pexidartinib (PLX3397) for TAM Assays

  2026-08-13

  Pexidartinib (PLX3397) provides a practical CSF1R perturbation tool for macrophage depletion, signaling studies, and tumor co-culture models. Paired with SPP1-focused phenotypic assays, it helps distinguish CSF1R-dependent macrophage biology from direct SPP1 modulation in cancer research.

7947 records 2/530 page Previous Next 12345 下5页 Last page